宏智生醫科技股份有限公司
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
The company takes EEG signal processing and artificial intelligence technology as the core, aiming to develop EEG-assisted diagnosis and medical services.
Founded Year
2019
Unified Business No.
82799334
Status
Active
Number of Employees
0
Total Paid-in
Capital
100,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
HippoScreen Neurotech Corp. (HNC) was established in March 2019 by Compal Computer's direct investment in the research team of Professor Liu, Yi-Hung. The company takes EEG signal processing and artificial intelligence technology as the core, aiming to develop EEG-assisted diagnosis and medical services. Its self-developed EEG amplifier cleared FDA 510(k) at the end of 2020, completed the TFDA review, and received approval for the medical device in March 2021, becoming the first medical-grade EEG amplifier manufacturer in Taiwan.
In addition, HippoScreen also passed ISO 13485 medical device quality management system certification, received a certificate from BSI in August 2022, and registered to the BSI certification website. Through this professional international standard certification, it is expected that HippoScreen will be able to enter the worldwide market as soon as possible.
In addition, HippoScreen also passed ISO 13485 medical device quality management system certification, received a certificate from BSI in August 2022, and registered to the BSI certification website. Through this professional international standard certification, it is expected that HippoScreen will be able to enter the worldwide market as soon as possible.
